[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attr":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,66],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100551878",false,"NCT06465810","Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis","A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis","MaesTTRo","Inclusion Criteria:\n\n* Patient willing and able to provide written informed consent to participate in the study\n* Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis\n* Aged ≥18 years at the time of signing the informed consent\n* Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)\n\nExclusion Criteria:\n\n* Concurrent participation in any interventional trial for ATTR amyloidosis\n* Involvement in the planning and\u002For conduct of the current study\n* Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)\n* Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers","ALL","18 Years","130 Years",{"count":20,"type":21},1850,"ESTIMATED","OBSERVATIONAL","The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.",[25,26,27,28,29,30],"Transthyretin Amyloidosis","ATTR-CM","ATTRv-PN","ATTR","ATTR-Mixed","hATTR",[32,33,34,35,36,37,38,39,40,41,42,28,43,44,45,46,47,48,49,50,51,52],"Amyloidosis","Transthyretin","Hereditary transthyretin-mediated (hATTR) amyloidosis","hATTR amyloidosis","Hereditary ATTR amyloidosis","Wild-type amyloidosis","wtATTR amyloidosis","ATTRv amyloidosis","ATTRwt amyloidosis","Polyneuropathy","Familial amyloid polyneuropathies","Transthyretin amyloidosis","TTR-mediated amyloidosis","Polyneuropathies","Amyloid neuropathies","Amyloid neuropathies, familial","Amyloidosis, familial","Eplontersen","Non-interventional","Observational","Real-world","RECRUITING","2026-06-19",{"date":56,"type":57},"2026-06-23","ACTUAL",{"date":59,"type":57},"2024-06-25",{"date":61,"type":21},"2031-12-29",{"name":63,"class":64},"AstraZeneca","INDUSTRY",74,{"id":67,"slug":4,"hasResults":10,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":16,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100638540","NCT07591038","PET\u002FCT Imaging in Carriers of TTR Mutations","Iodine-124 Evuzamitide PET\u002FCT Imaging in Carriers of TTR Mutations","EPIC-TTR","A. Pathogenic TTR Allele Carriers without HF\n\nInclusion:\n\n* men and women ages 30-80 who are pathogenic allele TTR carriers without history of HF (this will be assessed by study personnel and defined as : 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)\n* have already completed the protocol for NCT05489549 at UT Southwestern only\n\nExclusion:\n\n* a self-reported history or clinical history of HF\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* prior type 1 myocardial infarction\n* cardiac transplantation\n* liver transplantation\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* pregnancy or breastfeeding\n* patients taking heparin or heparin derivatives for anticoagulation\n* allergy to potassium iodide\n* known uncorrected thyroid disorder\n\nB. Subjects with symptomatic hATTR-CA (may be supplemented with other ATTR-CA genotypes including wild-type in the occasion of slow enrollment):\n\nInclusion:\n\n* men and women ages 30-80 who have symptomatic V122I hATTR-CA as determined by a history of HF (this will be assessed by study personnel and defined as : 1) history of hospitalization within the previous 12 months for management of HF; 2) an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)\n* hATTR-CA previously diagnosed histologically by amyloid staining and tissue typing with immunohistochemistry or mass spectrometry or by bone scintigraphy in without abnormal M-protein\n* TTR gene sequencing confirming the TTR variant\n* have already completed the protocol for NCT05489549 at UT Southwestern only\n\nExclusion:\n\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* cardiac transplantation\n* liver transplantation\n* history of type I myocardial infarction\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* patients taking heparin or heparin derivatives for anticoagulation\n* pregnancy or breastfeeding\n* allergy to potassium iodide\n* known uncorrected thyroid disorder\n\nC. Non-carrier race-matched controls:\n\nInclusion:\n\n* men and women ages 30-80 who are non-carriers without history of HF (this will be assessed by study personnel and defined as: 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or 3) No clinical diagnosis of HF from a treating clinician\n* have previously enrolled in the Dallas Heart Study\n\nExclusion:\n\n* a self-reported history or clinical history of HF\n* other known causes of cardiomyopathy\n* history of light-chain cardiac amyloidosis\n* prior type 1 myocardial infarction\n* cardiac transplantation\n* liver transplantation\n* body weight or habitus that exceeds the site-specific PET\u002FCT parameters\n* estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* inability to safely undergo PET\u002FCT\n* participating in a clinical trial for ATTR treatments or taking a fibril deleting agent\n* patients taking heparin or heparin derivatives for anticoagulation\n* pregnancy or breastfeeding\n* allergy to potassium iodide\n* known uncorrected thyroid disorder",true,"30 Years","80 Years",{"count":77,"type":21},80,"The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodine-124 evuzamitide, I-124E).\n\nParticipants will undergo a screening that includes a medical history review and completion of quality-of-life surveys. Once screening is complete, participants will undergo an imaging test called a positron emission tomography (PET) scan combined with computed tomography (PET\u002FCT) to make images of the body. The new radiotracer dye (I-124E, a radioactive contrast) will be used during the PET\u002FCT to make amyloidosis visible in the heart and body.",[28,80,81,82],"ATTR Gene Mutation","Cardiomyopathy","Transthyretin Mediated Amyloidosis (ATTR)",[84,85,86,87,88,89,28,90],"transthyretin","amyloidosis","carriers of abnormal gene","TTR","PET\u002FCT","evuzamitide","TTR gene","NOT_YET_RECRUITING","2026-05-15",{"date":94,"type":57},"2026-05-19",{"date":96,"type":21},"2026-08-01",{"date":98,"type":21},"2030-06-30",{"name":100,"class":101},"University of Texas Southwestern Medical Center","OTHER",1,""]